CRISPR Therapeutics AG
CRSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $4 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -97.5% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -7,177.1% | – | -6,548.4% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -11,404.8% | – | -16,611.3% | -170.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -11,973.1% | – | -15,722.1% | -106.6% |
| EPS Diluted | -1.17 | -2.4 | -1.58 | -0.44 |
| % Growth | 51.3% | -51.9% | -259.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |